Forte Biosciences Inc
FBRX9.435USD
-0.175-1.82%
交易中 （美東）報價延遲15分鐘
62.10M總市值
虧損本益比TTM
關於 Forte Biosciences Inc 公司
Forte Biosciences, Inc. 是一家專注於自身免疫和自身免疫相關疾病的臨牀階段生物製藥公司。該公司正在推進其候選產品 FB-102，這是一種專有分子，具有廣泛的自身免疫應用潛力，包括移植物抗宿主病 (GvHD)、白癜風和斑禿 (AA) 等適應症。該公司的 FB-102 項目專注於利用 CD122 拮抗劑解決與這些適應症有關的關鍵途徑。CD122 是 IL-2/IL-15 受體的亞基，IL-2/IL-15 受體是 NK 細胞和 T 細胞亞羣的關鍵調節劑。該公司擁有一項美國專利，用於施用革蘭氏陽性菌和革蘭氏陰性菌以及代謝物的組合，以治療多種皮膚病。該公司的子公司包括 Forte Subsidiary, Inc.、Forte Biosciences Emerald Limited 和 Forte Biosciences Australia Pty Ltd。
公司簡介
公司代碼FBRX
公司名稱Forte Biosciences Inc
上市日期Apr 13, 2017
CEODr. Paul A. Wagner, Ph.D.
員工數量14
證券類型Ordinary Share
年結日Apr 13
公司地址- -
城市- -
上市交易所NASDAQ Capital Market Consolidated
國家- -
郵編- -
電話- -
網址- -
公司代碼FBRX
上市日期Apr 13, 2017
CEODr. Paul A. Wagner, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
80.94K
+1.44%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.46K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
80.94K
+1.44%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.46K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月11日 週五
更新時間: 7月11日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Federated Hermes Global Investment Management Corp.
16.29%
Janus Henderson Investors
13.97%
Fred Alger Management, LLC
13.83%
Tybourne Capital Management (HK) Limited
11.95%
Ikarian Capital LLC
9.25%
Other
34.70%
持股股東
持股股東
佔比
Federated Hermes Global Investment Management Corp.
16.29%
Janus Henderson Investors
13.97%
Fred Alger Management, LLC
13.83%
Tybourne Capital Management (HK) Limited
11.95%
Ikarian Capital LLC
9.25%
Other
34.70%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
52.18%
Hedge Fund
33.25%
Private Equity
9.01%
Corporation
7.45%
Individual Investor
1.91%
Investment Advisor
1.55%
Research Firm
0.05%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
79
7.00M
106.27%
+1.62M
2025Q1
80
5.91M
89.79%
+471.51K
2024Q4
82
5.78M
90.44%
+3.18M
2024Q3
72
948.15K
58.94%
-63.60K
2024Q2
79
972.89K
60.86%
-40.06K
2024Q1
108
982.74K
67.53%
-37.22K
2023Q4
121
973.92K
67.03%
-54.29K
2023Q3
139
1.01M
71.78%
+97.73K
2023Q2
175
455.32K
54.14%
-352.22K
2023Q1
185
468.85K
56.07%
-1.69M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Janus Henderson Investors
920.00K
13.97%
+229.26K
+33.19%
Mar 31, 2025
Fred Alger Management, LLC
910.61K
13.83%
-223.34K
-19.70%
Mar 31, 2025
Tybourne Capital Management (HK) Limited
619.98K
9.42%
--
--
Mar 31, 2025
Ikarian Capital LLC
609.23K
9.25%
--
--
Mar 31, 2025
BVF Partners L.P.
594.28K
9.03%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
593.09K
9.01%
-6.91K
-1.15%
Mar 31, 2025
Nemean Asset Management, LLC
432.28K
6.57%
+432.28K
--
Nov 22, 2024
Cable Car Capital LLC
219.60K
3.34%
--
--
Mar 31, 2025
Woodline Partners LP
204.82K
3.11%
+547.00
+0.27%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
Fidelity Nasdaq Composite Index ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Alger 35 ETF
0%
iShares Micro-Cap ETF
佔比0.02%
Fidelity Nasdaq Composite Index ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
Alger 35 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Jun 15, 2020
Merger
15<1
Jun 15, 2020
Merger
15<1
公告日期
類型
比率
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Aug 22, 2024
Merger
25<1
Jun 15, 2020
Merger
15<1
Jun 15, 2020
Merger
15<1
Jun 15, 2020
Merger
15<1
Jun 15, 2020
Merger
15<1
